multiple indications, and 6 had no information. Twenty-two received MAC, 59 received RIC, and 4 were infused; information was unavailable for 2 patients. Seventy-three of 77 patients with DNA ligase IV deficiency, Cernunnos-XLF deficiency, or Nijmegen breakage syndrome received conditioning. Survival was 53 (69%) of 77 and was worse for those receiving MAC than for those receiving RIC (P 5 .006). Most deaths occurred early after transplantation, suggesting poor tolerance of conditioning. Survival in patients with AT was 25%. Forty-one (49%) of 83 patients experienced acute GvHD, which was less frequent in those receiving RIC compared with those receiving MAC (26/ Key words: Ataxia-telangiectasia, Cernunnos-XLF deficiency, DNA repair disorders, DNA ligase IV deficiency, hematopoietic stem cell transplantation, Nijmegen breakage syndrome Maintenance of genomic stability requires repair of DNA that was damaged through endogenous processes, such as meiotic and mitotic replication errors, and exogenous processes, including exposure to oxidizing radicals, DNA-damaging chemicals, and UV and ionizing radiation. Several repair pathways regulate the cell cycle and recognize and repair DNA damage. One of the most serious events to threaten genomic stability, DNA double-strand breaks (DNA-dsbs), if left unchecked will lead to loss of genomic material, mutagenesis, and oncogenesis or cell death. 1 Two pathways are used to repair such damage: homologous recombination, which functions primarily in dividing cells and the S phase and requires a homologous template to maintain replication accuracy, and non-template-dependent nonhomologous end-joining (NHEJ), which is used particularly during phases of the cell cycle when a homologous template is not present. The latter is an especially error-prone process, with some loss of DNA information at the site of the DNA-dsb. 2 Development of normal adaptive immunity requires generation of a wide range of T-and B-lymphocyte receptors to recognize unique antigen/MHC combinations and provides effective defense against a broad repertoire of pathogens. Many genetically diverse receptors are generated in the thymus and bone marrow by breaking, stochastically rearranging, and rejoining DNA sequences coding for antigen receptors, a process known as VDJ recombination. Additional diversity is created in B lymphocytes during immunoglobulin class-switch recombination and somatic hypermutation. The DNA repair mechanisms required to maintain somatic genomic stability are also used during lymphocyte VDJ recombination to repair intermediate DNA hairpins and physiologic DNA-dsbs created after activation of recombination-activating gene (RAG) 1 and 2.
3 Seven ubiquitously expressed proteins are associated with NHEJ-Ku70/80 and DNA protein kinase catalytic subunit, which stabilize the DNA break; the DNA endo/exonuclease Artemis, which is important for processing RAG-induced hairpin intermediate joins; and the DNA ligase IV and Cernunnos-XRCC4-like factor (Cernunnos-XLF), which together are responsible for the ligation step. Additionally, ataxia-telangiectasia mutated (ATM) and nibrin proteins are involved in the initial cell-cycle arrest and recruitment of NHEJ proteins to the breakage site (see Fig E1 in 
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1 SCID and combined immunodeficiencies, often associated with other developmental anomalies, particularly microcephaly in patients with DNA ligase IV and Cernunnos-XLF deficiency, as a result of the ubiquitous expression of these proteins. [6] [7] [8] [9] [10] [11] [12] [13] [14] Hematopoietic cell transplantation (HCT) is curative for T 2 B 2 NK 1 SCID, but best results with donor myeloid chimerism and long-term immune reconstitution are obtained if preparative chemotherapy is administered before transplantation. 15 However, in Artemis-deficient radiosensitive patients with SCID, although overall survival is equivalent to that of patients with RAG-deficient SCID, significant long-term sequelae result from administration of alkylating agents, which are required to gain donor stem cell engraftment with sustained long-term thymopoiesis. The use of alkylating chemotherapy does not result in increased short-term toxicities or increased transplant-related mortality, but long-term effects on growth and development are observed because of the effect of chemotherapy on other somatic cells that harbor the genetic defect.
15 Similar significant effects of chemotherapy are seen in patients with Fanconi anemia (OMIM 227650) and dyskeratosis congenita (OMIM 127550), both of which are DNA fragility syndromes. 16, 17 Given the systemic nature of the DNA-dsb defect in other DNA-dsb repair disorders and the finding that the radiosensitivity is generally more severe than in patients with Artemis deficiency, it is possible that preadministration of DNA-damaging chemotherapy before transplantation will lead to significant systemic morbidity and possible increased mortality.
Because of the primary immunodeficiency phenotype and the frequent occurrence of malignancy, a number of patients with DNA-dsb repair disorders have undergone HCT. [10] [11] [12] [13] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] To assess outcomes of HCT for DNA-dsb repair disorders, we surveyed patients undergoing transplantation for DNA ligase IV deficiency (LIG4), Cernunnos-XLF deficiency (XLF; or nonhomologous end-joining factor 1 [NHEJ1]), Nijmegen breakage syndrome (NBS), and ataxia-telangiectasia (AT) using baseline data from Stem Cell 30, 31 or 180/m 2 fludarabine (in 6 divided doses), 1.6 mg/kg busulphan (in 2 divided doses), and 40 mg/kg cyclophosphamide (in 2 divided doses). 32 The use of targeted agents, such as antibodies (eg, alemtuzumab) did not affect classification of the conditioning.
The primary outcome measured was survival. Secondary outcome measures sought were presence, severity, and outcome of GvHD, or other transplant-related complications.
Analysis
Significance of results was determined by using the Fisher exact test with 2 3 2 contingency tables. A 2-tailed P value of .05 or less was considered significant. Kaplan-Meier curves were created based on last known status at the time at which the questionnaire was received; cases in which survival was not listed have been excluded from the survival analysis. All statistics were calculated with GraphPad Prism 6 software (GraphPad Software, La Jolla, Calif).
RESULTS
Data were collected from 38 centers worldwide, culminating in 55 newly identified patients and 14 previously published patients with updated new information, producing new information on 69 patients. Available data from 18 previously published cases [10] [11] [12] [13] [14] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] were included, where possible, totaling 87 cases. The median age of patients at HCT was 48 months (range, 1.5-552 months), and 47 were male (54%).
Mutations in LIG4 were most commonly represented in 36 patients (32 unpublished or with new information, see Table E1 in this article's Online Repository at www.jacionline.org), 26 with NBN mutations (17 unpublished or with new information, see Table E2 in this article's Online Repository at www.jacionline.org), 17 with NHEJ1 mutations (12 unpublished or with new information, see Table E3 in this article's Online Repository at www.jacionline.org), and 8 with ATM mutations (all with new information, 2 previously published, updated in this report; see Table E4 in this article's Online Repository at www.jacionline.org). All patients received allogeneic hematopoietic stem cells, except 2 published patients who died immediately before HCT while receiving MAC but whose data were included in the study.
Information was provided on the primary reason for HCT in 83 patients (Fig 1) . Significant or repeated infections were the most commonly cited reason (29 [35%] patients, 12 with LIG4 mutations and 11 with NHEJ1 mutations), 13 (15%) patients underwent transplantation for bone marrow failure, and 21 (24%) patients underwent transplantation for malignancy (17 with NBN mutations). Thirteen (15%) patients underwent transplantation pre-emptively on the basis of an SCID-like diagnosis, 10 with LIG4 mutations. Five patients had a mixture of the above indications, and in 6 patients the reason for HCT was not available.
Twenty-two patients received MAC, and 59 received RIC, of which 30 were based on a modified Fanconi anemia conditioning regimen. Four patients received a stem cell infusion without prior conditioning; data were unavailable for 2 patients. Two received radiotherapy (5 and 2 Gy, respectively) as part of the conditioning regimen.
Survival
Of patients with LIG4, Cernunnos-XLF deficiency, and NBS, there were survival data for 77, of whom 73 received conditioning. Overall survival was 53 (69%) of 77 (Fig 2, A) , 2 of whom died from relapse of malignancy, resulting in a transplant-related survival of 71%. One patient with NBS rejected the graft and is alive with disease. One rejected and succumbed to malignancy. Survival among those receiving MAC was significantly worse at 41% (7/17) compared with 79% (44/56) for those receiving RIC (P 5.006; Fig 2, B) , describing 2 patients who died of malignancy relapse as survivors. There was no significant difference in transplant-related mortality between those who received a modified Fanconi or other RIC regimen (P 5 .13). The KaplanMeier curve demonstrates that the majority of deaths occur early in the course of transplantation, particularly in those receiving MAC, suggesting poor tolerance of the conditioning regimen.
In patients with AT, overall survival was 25%. Of the 2 patients who survived, both received a modified Fanconi conditioning regimen, and neither experienced GvHD, unlike all patients who received MAC. The 6 patients who died experienced GvHD grade 2 or 3 (67%), despite well-matched donors. Death was due to multiorgan failure, viral activation, or posttransplantation lymphoproliferative disorder (PTLD).
Transplant-related survival in the entire cohort for whom data were available was 66% (56/85), with a survival of 75% (45/60) after RIC and 32% (7/22) after MAC (P 5 .0006). There was no significant difference in outcome between those who underwent HCT for malignancy (12/22 survivors) or for other indications (37/57 survivors, P 5 .44). There was no significant difference in survivors for those receiving RIC (11/17) or MAC (1/5) conditioning when malignancy was the reason for HSCT (P 5 .14). There was also no significant difference in survivors for those receiving RIC (5/25) or MAC (4/9) when infection was the reason for HSCT (P 5 .09). There were too few patients who underwent transplantation for bone marrow failure to make a similar comparison.
There were no differences in survival between donor sources, irrespective of whether matched sibling, matched unrelated, or mismatched unrelated donors were used (18/25, 20/27, and 5/8, respectively). 
GvHD
Data on the presence or absence of acute graft-versus-host disease (aGvHD) was available for 83 patients; aGvHD was present in 41 (49%) of these. Of the reported patients with aGvHD, 24 (59%) had mild (grade 1-2) and 15 (37%) had severe (grade 3-4) aGvHD (a grade was unavailable for 2 patients). Rates of aGvHD were lower in the RIC group, 26 (46%) of 56 cases for whom data were available, compared with the MAC group, in whom 12 (57%) of 21 cases experienced aGvHD, although this was not statistically significant (P 5 .45). Three of 4 patients who received infused stem cells with no preconditioning experienced grade 1, 3, and 4 aGvHD respectively. There was no significant difference in survival between those experiencing grade 0 or 1 compared with those receiving grade 2 to 4 aGvHD (P 5 .22).
Mortality
Overall mortality was 29 (34%) of 84; information was unavailable for 2 previously published patients. 24 Two patients died of multiorgan failure during the conditioning process; both received full MAC. Eleven others died of multiorgan failure after transplantation, making multiorgan failure the most common cause of death (45%). Eleven deaths were predominantly infectious (38%).
Other complications
The most common non-aGvHD complication was viremia caused by adenovirus, cytomegalovirus, EBV, or a combination, which was reported in 24 (30%) of 79 patients, 6 of whom died. There were 6 (8%) cases of EBV-related PTLD. Six (8%) patients experienced severe mucositis, and 14 (18%) had chronic graft-versus-host disease (cGvHD). Seven patients rejected the graft: 2 after stem cell infusion (1 with serotherapy), 2 after T lymphocyte-depleted transplantations (1 MAC and 1 RIC), and 3 after MAC or RIC transplantations. Patients receiving RIC were less likely to experience severe mucositis, veno-occlusive disease, or PTLD than those who received MAC (7/59 vs 8/22, P 5 .0215).
Follow-up
Given the retrospective and multi-institutional nature of the study, detailed information regarding long-term (>5 years) follow-up was scarce. Median length of follow-up was 35 months (range, 2-168 months). No secondary malignancies were reported during the follow-up period, which, although short overall, includes patients with almost 15 years of follow-up. Pre-existing growth restriction and developmental issues appear to remain after HCT: a more detailed examination would be required to determine whether HCT ameliorates these features. A predisposition to infection or hematologic cytopenia existing before HCT appears to have been abolished.
DISCUSSION
Many patients with DNA-dsb repair defects exhibit immunodeficiency, ranging from mild to severe combined immunodeficiency, and are at increased risk of lymphoid malignancy. Allogeneic HCT is curative for many immunodeficiencies. 33 Establishment of effective DNA repair mechanisms in lymphoid progenitors leading to restoration of functional adaptive immunity might prevent the future development of lymphoid malignancy in this cohort of patients. Lymphoid malignancy is difficult to treat effectively when established because of the aggressive nature of the tumors and poor tolerance of patients to cytotoxic radiotherapy and chemotherapy. 34 Therefore it is a reasonable strategy to consider HCT in these patients. However, because most patients have some residual immunity and NK cells are present even in the SCID phenotype, rejection and poor stem cell engraftment are likely without some preparative cytoreductive preconditioning. However, the systemic nature of the genetic defect increases the risk of substantial morbidity or mortality from chemotherapy or ionizing radiation administered before transplantation. Only a few small case series of patients with DNA-dsb repair defects undergoing HCT have been published. To date, there has been no formal large case series from which to gauge experience.
We now report a multi-institutional retrospective survey on outcomes of HCT for 55 previously unpublished patients and update information for 18 previously reported patients with DNA-dsb repair defects. We have demonstrated that HCT can correct the hematopoietic defect and underlying immunodeficiency. Furthermore, we have demonstrated that survival is significantly superior when RIC is used. It is likely that chemotherapy agents, especially alkylating agents, induce systemic double-strand breaks, which are not readily repaired because of the underlying genetic defect. These systemic double-strand breaks can contribute to the early mortality seen after myeloablative therapy. This intolerance, which manifests clinically as severe toxicity sometimes followed by higher-grade GvHD, suggests that when considering HCT, an RIC regimen should be used in patients with known ionizing radiation sensitivity and/or proved diagnosis of a DNA-dsb repair defect and that radiotherapy should be omitted. Given the equivalence of outcome results when comparing modified Fanconi anemiabased regimens with other reduced-intensity regimens, the former might be preferred. Longer-term follow-up is required to determine the effect of HCT on future prevention of lymphoid malignancy.
The rate of aGvHD overall was 49%, of which 37% was grade 3 or 4. The rate of cGvHD was 18%. The incidence of severe (grade 3-4) aGvHD and cGvHD is higher than that reported for transplantation of patients with other primary immunodeficiencies. [35] [36] [37] [38] It is not clear whether this is due to the greater use of matched unrelated donors rather than matched sibling donors (although in the modern era outcome of HCT with matched siblings or unrelated donors approaches equivalence), particularly in those receiving RIC. Significant comorbidities might also have contributed to the increased incidence of GvHD. However, it could be that the underlying molecular defect causing impaired DNA repair and reduced cellular repair capability predisposes to GvHD after cellular damage, as found in patients with Fanconi anemia or dyskeratosis congenita. 17, 39 Patients showed a range of other early post-HCT complications in addition to GvHD. Most common were viral reactivations, which in the case of EBV led to PTLD in 6 patients. Severe mucositis and veno-occlusive disease were commonly encountered.
Three patients experienced veno-occlusive disease, and 2 who underwent transplantation for malignancy experienced relapse of the primary malignancy. Three patients had autoimmune thyroid disease, and autoimmune cytopenias were also manifest.
Within this patient cohort, there are few data on long-term follow-up. Transplantation, unsurprisingly given the systemic nature of the defect, appears not to improve the effects of the primary disease on growth or neurologic development. It might be, as in patients with Artemis-SCID, that use of any alkylating agent leads to long-term sequalae. 15 It will be difficult to predict whether growth or development has been improved or deteriorated as a result of chemotherapy given the scarce data available on the natural history of these diseases and the variability of the phenotype already reported. However, determining the long-term and late beneficial and adverse effects of HCT in DNA-dsb defects will be important to provide details about the utility of this treatment approach. A recent report on a cohort of patients with mutations in NBN documented poor survival in those with malignancy. 24 Given the good survival outcome in this cohort among those who received RIC regimens, a pre-emptive approach to transplantation can be considered. Therefore long-term follow-up to determine the frequency of secondary malignancies will be of particular importance; although it has not been reported thus far in other primary immunodeficiency transplant series, it is a well-recognized complication in patients undergoing transplantation for Fanconi anemia. 39 Although the outcome of HCT in patients with mutations in LIG4, NBN, and NHEJ1 is favorable, particularly when RIC regimens are used, the data for patients with AT undergoing HCT are disappointing. Whether this is specifically due to the use of MAC regimens or the presence of malignancy, precipitating transplantation as a therapeutic option is not clear. With current results, it is difficult to recommend HCT as a treatment option for patients with AT, except in clinical trials. In contrast, patients with the other conditions described have transplantation outcomes similar to those with other primary immunodeficiencies when choosing RIC. Therefore transplantation could be considered more favorably as a pre-emptive therapeutic approach, particularly if radiotherapy is omitted from the conditioning regimen and low-intensity conditioning regimens are used. However, the high rate of posttransplantation complications, including GvHD, remains a concern and should drive the development of alternative low or nontoxic conditioning approaches that relieve these patients of the deleterious effects of alkylating therapy but enable full T-and B-lymphocyte reconstitution. In the meantime, careful follow-up is required to observe further systemic benefits from transplantation, if any, and importantly to monitor for long-term adverse events. In the future, gene therapy might be an acceptable alternative treatment strategy for this group of patients. 
